The domestic equity barometers sharply pared early losses and traded with minor cuts in morning trade. The Nifty hovered near the 15,300 mark. Meanwhile, pharma shares extended their losing streak for the second day in a row.
At 10:24 IST, the barometer index, the S&P BSE Sensex, was down 159.71 points or 0.31% to 51,336.08. The Nifty 50 index fell 66.75 points or 0.43% to 15,293.85.
In the broader market, the S&P BSE Mid-Cap index slipped 1.04% while the S&P BSE Small-Cap index declined 1.06%.
The market breadth, indicating the overall health of the market, was weak. On the BSE, 792 shares rose and 2186 shares fell. A total of 108 shares were unchanged.
Fears loomed across markets that the rising attempts of central banks to curb inflation would lead to a slowdown in global economic growth and could possibly lead to a recession.
Buzzing Index:
The Nifty Pharma index fell 2.43% to 11,773.10. The index has declined 3.98% in two sessions.
Dr Reddys Laboratories (down 4.23%), Sun Pharmaceuticals Industries (down 1.94%), Biocon (down 1.79%), Cipla (down 1.75%) and Divis Laboratories (down 1.62%) were the top index losers.
Further, Ipca Laboratories (down 1.58%), Torrent Pharmaceuticals (down 1.5%), Gland Pharma (down 1.47%), Aurobindo Pharma (down 1.43%) and Strides Pharma Science (down 1.29%) declined.
Meanwhile, Granules India (up 1.75%), Abbott India (up 0.34%) and Glenmark Pharmaceuticals (up 0.18%) edged higher.
Stocks in Spotlight:
Grasim Industries shed 0.27%. Pavan Jain has been appointed as the company's new CFO and key Managerial Personnel, effective August 15.
Vakrangee fell 2.58%. The company has entered into a seller agreement with Decathlon Sports India to offer a complete range of sports equipments and products to the unserved and underserved population of India.
Ritesh Properties & Industries lost 0.47%. The company's board approved a sub-division of equity share having face value of Rs 10 each into equity shares of face value of Re 1 each.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app